Manmeet Ahluwalia MD, FACP, MBA
Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, FloridaDr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.
Recent Contributions to PracticeUpdate:
- Nivolumab Plus Bevacizumab for Recurrent Glioblastoma.
- Depatuxizumab Mafodotin for EGFR-Amplified Glioblastoma
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- 2020 Top Stories in Brain Cancer: Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
- Vocimagene Amiretrorepvec Plus Flucytosine vs Standard of Care Following Tumor Resection in Patients With Recurrent High-Grade Glioma
- Practice-Impacting Data on Managing Lung Cancer Brain Metastases
- Sensitivity to Temozolomide in IDH-Wildtype Glioblastoma
- Updates in the Management of Lung Cancer Associated Brain Metastases With Targeted Agents
- Updates in the Management of Lung Cancer Associated Brain Metastases With Immunotherapy
- Targeting IDH Mutations in Glioma: Implications of New Data